Top Biotech Deals in January 2026

Why It Matters

The activity signals that despite fewer outright mergers, biotech firms are aggressively investing in high‑value, innovative assets to accelerate pipelines and diversify risk, reshaping the industry’s growth trajectory.

Key Takeaways

• Amgen acquires Dark Blue for $840 M, adding AML degrader
• GSK purchases RAPT for $2.2 B, expanding anti‑IgE pipeline
• Small‑molecule licensing deals total over $1 B this month
• AI‑driven collaborations exceed $1.8 B across biotech firms
• Bispecific antibody deals reach $5 B in upfront payments

Pulse Analysis

January 2026 marked a modest dip in headline‑making M&A activity, yet the transactions that did close were strategically significant. Amgen’s $840 million acquisition of Dark Blue Therapeutics adds a protein‑degrader program for acute myeloid leukemia to its oncology portfolio, while GSK’s $2.2 billion purchase of RAPT Therapeutics secures an anti‑IgE monoclonal antibody targeting food‑allergy and chronic urticaria. Charles River Laboratories’ $510 million move to own PathoQuest gives the CRO a non‑animal testing platform amid supply‑chain scrutiny, and Barcelona‑based Esteve’s undisclosed infusion‑therapy buy expands its U.S. footprint. These deals underline a focus on high‑value assets that can immediately strengthen pipelines.

The licensing arena surged, with small‑molecule, bispecific, and genomic deals accounting for the bulk of activity. Formation Bio and Jiangsu Chia Tai Feng Hai locked in up to $500 million for an oral anti‑inflammatory candidate, while Insilico Medicine signed three collaborations totaling more than $1.8 billion, leveraging its Pharma.AI platform for metabolic and CNS targets. Bispecific antibody agreements, from Boehringer Ingelheim to AbbVie, delivered over $5 billion in upfront and milestone potential, reflecting confidence in dual‑target approaches for inflammatory bowel disease and solid tumours. Meanwhile, Moderna’s partnership with Recordati and Lilly’s $1.12 billion deal with Seamless Therapeutics illustrate sustained appetite for mRNA and programmable recombinase technologies.

Investors are interpreting these patterns as a shift toward asset‑light expansion and risk‑mitigation through external innovation. By licensing early‑stage programs, companies can access cutting‑edge modalities—such as AI‑guided drug design, long‑read sequencing, and cell‑therapy platforms—without the full cost of discovery. The concentration of capital in antibody‑centric and genomic deals suggests that the market expects higher clinical success rates and premium pricing for differentiated therapies. As regulatory pathways evolve and reimbursement models reward precision medicine, the pace of such collaborations is likely to accelerate, making deal‑making a critical barometer of biotech valuation and pipeline robustness.